D'Haens G, Ferrante M, Vermeire S, et al. - Researchers have explored how reliably calprotectin levels represent mucosal disease activity since mucosal healing has become a target of treatment in inflammatory bowel disease (IBD). A total of 126 patients with IBD and 32 patients with irritable bowel syndrome (IBS) who needed colonoscopy delivered a sample of feces prior to the start of bowel cleansing. Data reported that the median fecal calprotectin levels were 175 μg/g in CD, 465 μg/g in UC, and 54 μg/g in IBS. A cutoff value of 250 μg/g showed the presence of large ulcers with a sensitivity of 60.4% and a specificity of 79.5% in CD using ROC statistics. A fecal calprotectin > 250 μg/g gave a sensitivity of 71.0% and a specificity of 100.0% for active mucosal disease activity in UC. The levels of fecal calprotectin significantly correlate with IBD endoscopic disease activity. The test appears to be useful for evaluating endoscopic activity and remission in clinical practice.